| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
COLOGNE, Germany—Gene-transfer specialist amaxa and Lafayette, Colo.-based Dharmacon, a division of Fisher Biosciences, recently announced an agreement to co-promote Dharmacon's siRNA libraries with the German company's Nucleofactor technology.
 
The hope is that the combined technologies will further facilitate the application of RNAi-based gene silencing in drug discovery and development by improving the high-throughput transfer of nucleic acids into cells.
 
According to Dr. William Marshall, VP of technology and business development at Fisher Biosciences, the two companies will work closely to provide customers with coordinated technical service, pre-tested protocols, and application models.
 
"We believe Dharmacon provides excellent quality siRNA, and that made the company an obvious choice for partnering," Rainer Christine, CEO of amaxa, added. "By working closely with Dharmacon, we can help researchers accelerate the speed and accuracy of their experiments using siRNA."

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

GreenCooling

Thermo Scientific™ Centrifuges with GreenCool Technology

Next-generation natural refrigerant cooling system for centrifuges, offering a lower Global Warming Potential and reduced energy consumption.
Clear sample tubes are shown in a clear tote with red lids in a sample prep robot with a blue and silver industrial lab background.

The crucial role of sample preparation in biotherapy manufacturing

Discover how better sample preparation can unlock improved assay accuracy and analytical results.
A black mosquito is shown on pink human skin against a blurred green backdrop.

Discovering deeper insights into malaria research

Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue